IP Library Granted Patent US 9,440,991
Granted Patent B2
US 9,440,991 · App. 14/576,143 · Granted Sep 13, 2016

Synthesis of an antiviral compound

Inventors: Amy Cagulada (San Francisco, CA); Johann Chan (San Mateo, CA); Lina Chan (Foster City, CA); Denise A. Colby (San Francisco, CA); Kapil Kumar Karki (Foster City, CA); Darryl Kato (San Francisco, CA); Katie Ann Keaton (Burlingame, CA); Sudha Kondapally (Foster City, CA); Chris Levins (San Mateo, CA); Adam Littke (Oakland, CA); Ruben Martinez (San Diego, CA); Dominika Pcion (San Francisco, CA); Troy Reynolds (San Francisco, CA); Bruce Ross (El Granada, CA); Michael Sangi (San Mateo, CA); Adam J. Schrier (Redwood City, CA); Pamela Seng (San Francisco, CA); Dustin Siegel (San Carlos, CA); Nathan Shapiro (Belmont, CA); Donald Tang (Millbrae, CA); James G. Taylor (San Mateo, CA); Jonathan Tripp (Foster City, CA); Andrew W. Waltman (San Francisco, CA); Lawrence Yu (Foster City, CA)
Assignee: Gilead Sciences, Inc.
C07D498/16C07C51/09C07C209/00C07C227/02C07D403/12C07D453/02C07K5/0808
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,440,991
App. No.
14/576,143
Granted
Sep 13, 2016
Kind
B2
Abstract

The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.

Claims (77)

1. A process for preparation of a compound of formula V:

or a salt thereof;

comprising contacting a compound of formula III or a salt thereof, with a compound of formula IV:

under O-arylation conditions to provide the compound of formula V or a salt thereof, wherein R is C 1-6 alkyl, PG is a protective group, and R 1 is a leaving group.

2. A process for preparation of a compound of formula I:

or a pharmaceutically acceptable salt thereof; comprising:

a) preparing a compound of formula V:

or a salt thereof according to the process of claim 1 ;

b) subjecting the compound of formula V or a salt thereof to N-deprotection conditions to provide a compound of formula VI:

or a salt thereof;

c) contacting the compound of formula VI or a salt thereof with a compound of formula VII:

or a salt thereof,

under amide coupling conditions to provide a compound of formula VIII:

or a salt thereof;

d) performing ring closing metathesis of the compound of formula VIII or a salt thereof to provide a compound of formula IX:

or a salt thereof;

e) hydrogenating the compound of formula IX or a co-crystal, or a salt thereof in presence of a catalyst to provide a compound of formula X:

or a salt thereof;

f) hydrolyzing the compound of formula X or a salt thereof to provide a compound of formula XI:

or a salt thereof;

g) contacting the compound of formula XI or a salt thereof with a compound of formula

or a salt thereof;

under amide coupling conditions to provide the compound formula I:

or a pharmaceutically acceptable salt thereof, wherein R is C 1-6 alkyl, PG is a protective group, and R 1 is a leaving group.

3. A process for preparation of a compound of formula I:

or a pharmaceutically acceptable salt thereof, comprising:

a) preparing a compound of formula V

or a salt thereof according to the process of claim 1 ;

b) contacting the compound of formula V or a salt thereof with an acid under N-deprotection conditions to provide a compound of formula VI:

or a salt thereof;

c) contacting the compound of formula VI or a salt thereof with a compound of formula VII:

or a salt thereof,

under amide coupling conditions to provide a compound of formula VIII:

or a salt thereof;

d) hydrolyzing the compound of formula VIII or a salt thereof to provide a compound of formula XVIII:

or a salt thereof;

e) performing ring closing metathesis of the compound of formula XVIII or a salt thereof in presence of a catalyst to provide a compound of formula XIX:

or a salt thereof;

f) hydrogenating the compound of formula XIX in presence of a catalyst to provide a compound of formula XI:

or a salt thereof;

g) contacting the compound of formula XI or a salt thereof with a compound of formula XII:

or a salt thereof;

under amide coupling conditions to provide the compound formula I:

or a pharmaceutically acceptable salt thereof, wherein R is C 1-6 alkyl, PG is a protective group, and R 1 is a leaving group.

4. A process for preparation of a compound of formula XV:

or a salt thereof, comprising contacting a compound of formula XIII:

or a salt thereof,

with a compound of formula XIV:

or a salt thereof,

under cross-metathesis conditions to provide the compound of formula XV or a salt thereof, wherein R is C 1-6 alkyl and PG is a protective group.

5. A process for preparation of a compound of formula I:

or a pharmaceutically acceptable salt thereof, comprising:

a) preparing a compound of formula XV:

or a salt thereof according to the process of claim 4 ,

b) hydrogenating the compound of formula XV or a salt thereof in presence of a catalyst to provide a compound of formula XVI:

or a salt thereof;

c) subjecting the compound of formula XVI or a salt thereof to N-deprotection conditions to provide a compound of formula XVII:

or a salt thereof;

d) contacting the compound of formula XVII with an amide coupling agent under lactamization conditions to give a compound of formula X:

or a salt thereof;

e) hydrolyzing the compound of formula X or a salt thereof to provide a compound of formula XI:

or a salt thereof; and

contacting the compound of formula XI or a salt thereof with a compound of formula XII:

or a salt thereof under amide coupling conditions to provide the compound formula I:

or a salt thereof, wherein R is C 1-6 alkyl and PG is a protective group.

6. A process for preparation of a compound of formula V-v:

a salt thereof, comprising:

hydrolyzing the compound of formula A-b:

or a salt thereof to provide a compound of formula A-c:

or a salt thereof;

b) contacting the compound of formula A-c or a salt thereof with dicyclohexylamine to provide a compound of formula A-g:

or a salt thereof;

c) contacting A-g or a salt thereof with cinchonidine to provide a compound of formula A-h:

or a salt thereof;

d) subjecting A-h or a salt thereof to Curtius rearrangement in presence of tert-butanol to provide a compound of formula A-i:

or a salt thereof; and

e) hydrolysis of A-i or a salt thereof to provide V-v a salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2022
From: GILEAD PHARMASSET LLC
To: GILEAD SCIENCES, INC.
Reel/Frame 059785/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2019
From: GILEAD SCIENCES, INC.
To: GILEAD PHARMASSET LLC
Reel/Frame 048958/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: CAGULADA, AMY; CHAN, JOHANN; CHAN, LINA; COLBY, DENISE A; KARKI, KAPIL KUMAR; KATO, DARRYL; KEATON, KATIE ANN; KONDAPALLY, SUDHA; LEVINS, CHRIS; LITTKE, ADAM; MARTINEZ, RUBEN; PCION, DOMINIKA; REYNOLDS, TROY; ROSS, BRUCE; SANGI, MICHAEL; SCHRIER, ADAM J.; SENG, PAMELA; SIEGEL, DUSTIN; SHAPIRO, NATHAN; TANG, DONALD; TAYLOR, JAMES G.; TRIPP, JONATHAN; WALTMAN, ANDREW W.; YU, LAWRENCE
To: GILEAD SCIENCES, INC.
Reel/Frame 035096/0160 →
Continuity (2)
Provisional Application 61920446 · Dec 23, 2013
Related Publication 20150175626A1 · Jun 25, 2015